Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Who can take part

• Age ≥18 years
• Clinical and/or histopathologic diagnosis of LPP
• Presence of scalp pruritus
• Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1
• Ability and willingness to provide written informed consent and comply with study procedures
• Willingness to undergo optional scalp biopsy for research purposes

Who cannot take part

• Prior use of nemolizumab
• Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks)
• Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks)
• Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or
• Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks)
• Any other current treatments for hair loss (e.g., oral/topical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed
• Any systemic disease associated with hair loss
• Inflammatory or infectious scalp disease that may interfere with the study
• Any other conditions associated with pruritus
• Allergy or hypersensitivity to nemolizumab or any excipients
• Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results
• Other forms of alopecia that may interfere with study assessments
• biologics
• Pregnancy or unwillingness to use highly effective contraception